A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection

PharmacoEconomics

Volumn 28, Issue SUPPL. 1, 2010, Pages 1-16

  Mauskopf, Josephine ^a   Annemans, Lieven ^b   Hill, Andrew M ^c,d   Smets, Erik ^e  

^a RTI HEALTH SOLUTIONS   (United States)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d TIBOTEC BVBA   (Belgium)

^e JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DARUNAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR PLUS TIPRANAVIR; VIRUS RNA;

AUSTRIA; BELGIUM; BUDGET; CANADA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; FRANCE; GERMANY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; NETHERLANDS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLAND; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REVIEW; SENSITIVITY ANALYSIS; SPAIN; SWEDEN; SWITZERLAND; UNITED KINGDOM; UNITED STATES;

EID: 78650731033     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11587410-000000000-00000     Document Type: Review

References (66)

1. US Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents (USDHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2008 Jan 29 [online]. Available from URL: Http://AIDSinfo.nih.gov [Accessed 2009 Dec 10]
2. Ghatnekar O, Hjortsberg C, Gisslén M, et al. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a university clinic in Sweden. PharmacoEconomics 2010; 28 Suppl. 1: 49-57
3. Levy A, Johnston K, Annemans L, et al. The impact of disease stage on direct medical costs of HIVmanagement: A review of the international literature. PharmacoEconomics 2010; 28 Suppl. 1: 35-47
4. Colin X, Lafuma A, Costagliola D, et al. Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France. PharmacoEconomics 2010; 28 Suppl. 1: 183-97
5. Mauskopf JA, Kitahata M, Kauf T, et al. HIV antiretroviral treatment: Early versus later. J Acquir Immune Defic Syndr 2005; 39: 562-9
6. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-31
7. Schackman BR, Freedberg KA, Weinstein MC, et al. Costeffectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002; 162: 2478-86
8. Sax PE, Losina E,Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr 2005; 39: 69-77
9. Hornberger J, Green J, Wintfeld N, et al. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy. HIV Clin Trials 2005; 6: 92-102
10. Hornberger J, Kilby JM, Wintfeld N, et al. Costeffectiveness of enfuvirtide in HIV therapy for treatmentexperienced patients in the United States. AIDS Res Hum Retroviruses 2006; 22: 240-7
11. Simpson KN, Chumney ECG, Hicks CB, et al. Cost effectiveness of tipranavir in treatment-experienced HIV patients in the USA [poster PIN10]. 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2006 May 20-24; Philadelphia, Pennsylvania, USA
12. Mauskopf J, Brogan A, Martin S, et al. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV- 1-infected adults in the USA. PharmacoEconomics 2010; 28 Suppl. 1: 83-105
13. Brogan A, Mauskopf J, Talbird S, et al. US cost effectiveness of darunavir/ritonavir 600/100mg bid in treatmentexperienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITANtrial. Pharmaco- Economics 2010; 28 Suppl. 1: 129-46
14. Mauskopf J. Meeting the NICE requirements: A Markov model approach. Value Health 2000; 3: 287-93
15. Mauskopf JA, Tolson JM, Simpson KN, et al. Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. J Acquir Immune Defic Syndr 2000; 23: 302-13
16. Colin X, Lafuma A, Costagliola D, et al. The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France. PharmacoEconomics 2010; 28 Suppl. 1: 59-68
17. Pozniak A, Jayaweera D, Hoy J, et al. Efficacy of darunavir/ritonavir in treatment-experienced HIV-1-infected patients at 96 weeks in the POWER 1 and 2 trials [abstract P7.2/0]. 11th European AIDS Conference; 2007 October 24-27; Madrid, Spain
18. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatmentexperienced patients: 24 week results of POWER 3. J Acquir Immune Defic Syndr 2007; 46: 24-31
19. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369 (9568): 1169-7
20. Katlama C, Bellos N, Grinsztejn B, et al. POWER 1 and 2: Combined final 144-week efficacy and safety results for darunavir/ritonavir 600/100mg bid in treatment-experienced HIV patients [abstract]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9-13; Glasgow, UK
21. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir/ritonavir compared with that of lopinavir/ritonavir at 48 weeks in treatment-experienced, HIV infected patients in TITAN: A randomized controlled Phase III trial. Lancet 2007; 370: 49-58
22. Pozniak A, Arasteh K, Molina JM, et al. POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir 600/100 mg bid in treatment-experienced patients [abstract]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9-13; Glasgow, UK
23. Arastéh K, Grinsztejn B, de Béthune MP, et al. Efficacy analysis of darunavir/r in treatment-experienced POWER 3 patients at Week 96 [abstract P7.2/05]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, Spain
24. Banhegyi D, Katlama C, da Cunha C, et al. Phase III TITAN week 96 final analysis: Efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment experienced patients [abstract]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9-13, Glasgow, UK
25. Moeremans K, Annemans L, Löthgren M, et al. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. PharmacoEconomics 2010; 28 Suppl. 1: 107-28
26. Moeremans K, Hemmett L, Hjelmgren J, et al. Cost effectiveness of darunavir/ritonavir 600/100mg bid in treatmentexperienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. PharmacoEconomics 2010; 28 Suppl. 1: 147-67
27. Hill AM, Clotet B, Johnson M, et al. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: The POWER experience. PharmacoEconomics 2010; 28 Suppl. 1: 69-81
28. Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH guidelines for the evaluation of health technologies: Canada, 3rd ed. 2006. Available at: Http://www.cadth.ca/media/pdf/186-EconomicGuidelines-e.pdf [Accessed 2010 Jun 30]
29. National Institute for Health and Clinical Excellence (NICE). Single technology appraisal specification for manufacturer/sponsor submission of evidence. 2009. Available at: Http://www.nice.org.uk/media/E29/DF/ SpecificationFor ManufacturerSponsorSubmissionofEvidenceDraft.pdf [Accessed 2010 Jun 30]
30. Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee, version 4.2. 2007. Available at: Http://www.health.gov.au/internet/main/publishing.nsf/ Content/pbacguidelines-index [Accessed 2010 Jun 30]
31. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal; 2008 June [online]. Available from URL: Http://www. nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune 2008.pdf [Accessed 2009 Dec 10]
32. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000; 20: 332-42
33. Towse A. What is NICE's threshold? An external view. Chapter 2. In: Devlin N, Towse A, editors. Cost effectiveness thresholds: Economic and ethical issues. London: King's Fund/Office for Health Economics, 2002
34. Sacristan JA, Oliva J, Del Llano J, et al. Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002; 16: 334-43
35. Chapman RH, Stone PW, Sandberg EA, et al. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies.MedDecisMaking 2000; 20: 451-67
36. BHIVA Writing Committee. British HIV Association (BHIVA). Guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Medicine 2006; 7: 487-503
37. European AIDS Clinical Society (EACS). 2009 Guidelines for the clinical management and treatment of HIVinfected adults in Europe; [online]. Available from URL: Http://www.europeanaidsclinicalsociety.org/guidelinespdf/EACS- EuroGuidelines2009FullVersion.pdf [Accessed 2009 Dec 10]
38. International AIDS Society USA (IAS-USA). Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-43
39. Basu RP, Grimes RM, Helmy A. Cost to achieve an undetectable viral load using recommended antiretroviral regimens. HIV Clin Trials 2006; 7: 309-18
40. Ruof J, Dusek A, DeSpirito M, et al. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients. Clin Drug Invest 2007; 27: 469-79
41. Lamy A, Jonsson B, Weintraub WS, et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil 2004; 11: 460-5
42. Kumar S, Williams AC, Sandy JR. How do we evaluate the economics of health care? Eur J Orthod 2006; 28: 513-19
43. Shih YC, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. PharmacoEconomics 2007; 25: 577-90
44. IQWiG (Instutut für Qualität und Wirtschaftlichkeit im Gesundheitswesen-Institute for Quality and Efficiency in Health Care). Methods for assessment of the relation of benefits to costs in the German statutory health care system. Version 1, 24th January, 2008
45. Annemans L, Hill A, Smets E, et al. Cost-effectiveness of current treatment options in treatment-resistant HIV/AIDS patients in the German setting [abstract PE19.5/5]. 12th European AIDS Conference; 2009 Nov 11-14, Cologne, Germany
46. Brogan A, Soorapanth S, Donatz V, et al. Comparative costefficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany [abstract PIN48]. 12th AnnualMeeting of the International Society for Pharmacoeconomics and Outcomes Research; 2009 October 24-27; Paris, France
47. Soorapanth S, Brogan A, Mrus J, et al. Comparative costefficacy analysis of darunavir/r for first-line treatment ofHIV infection in theUnited States.Value in Health 2009; 12:A112
48. Smets E, Stoll M, Hill A, et al. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany [abstract PE19.5/3]. 12th European AIDS Conference; 2009 Nov 11-14, Cologne, Germany
49. Hill AM, Gebo K, Hemmett L, et al. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: Evidence fromPOWER. PharmacoEconomics 2010; 28 Suppl. 1: 169-81
50. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individualswith virological failure to all three antiretroviral-drug classes. Lancet 2004; 364 (9428): 51-62
51. Phillips AN, Lundgren JD. The CD4 lymphocyte count and risk of clinical progression: The T cell in HIV infection and disease. Curr Opin HIV AIDS 2006; 1: 43-9
52. Holkmann Olsen C, Gatell J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19: 319-30
53. Weber R, Friis-Moller N, Sabin C, et al. HIV and non-HIVrelated deaths and their relationship to immunodeficiency: The D:A:D study [abstract 595]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston, MA, USA
54. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44: 990-7
55. Health Protection Agency (HPA) Center for Infections. A complex picture. HIV and other sexually transmitted infections in the United Kingdom; 2006 [online]. Available from URL: Http://www.hpa.org.uk/publications/2006/hiv-sti- 2006/default.htm [Accessed 2009 Dec 10]
56. England R. Are we spending too much on HIV? BMJ 2007; 334: 344
57. de Lay P, Greener R, Izazola JA. Are we spending too much on HIV? BMJ 2007; 334: 345
58. Harling G, Wood R, Beck EJ. Efficiency of interventions in HIV infection, 1994-2004. Dis Manage Health Outcomes 2005; 13: 371-94
59. BeckEJ,MinersAH, TolleyK. The cost ofHIVtreatment and care. A global review. PharmacoEconomics 2001; 19: 13-39
60. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. New Engl J Med 2007; 356: 1723-35
61. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008; 371: 1417-26
62. DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naïve HIV-1-infected patients at week 48: ARTEMIS [abstract H-718b]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 17-20; Chicago, IL, USA.
63. Berger DS, Northland R, Scribner A, et al. Effect of baseline factors on virological response to darunavir/r and lopinavir/r at week 48 in TITAN [abstract P7.3/27]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, Spain
64. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. J Acquir Immune Defic Syndr 2002; 31 Suppl.: S123-7
65. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: A controlled, randomized study in antiretroviral-naïve, HIV-1-infected patients. Antiviral Ther 2003; 8: 339-46
66. Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrob Chemother 2006; 58: 235-42